Physician profile
Shlomo Pascal
NPI 1124171616
$8,553.94
in general payments reported to CMS, 2019-2025
26 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $349 · 2021: $937 · 2022: $660 · 2023: $1,349 · 2024: $2,706 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,922 · Consulting Fee: $880 · Travel and Lodging: $270 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,922.14 |
| Consulting Fee | $880.00 |
| Travel and Lodging | $270.00 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,219.85 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,589.25 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $1,014.17 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $746.98 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $666.90 | 2020-2025 | Caplyta |
| Abbvie INC. | $544.95 | 2021-2025 | |
| Axsome Therapeutics, INC. | $420.99 | 2024-2025 | Auvelity |
| Alkermes, INC. | $314.59 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $252.63 | 2024-2025 | Cobenfy |
| Allergan, INC. | $148.35 | 2019-2020 | |
| Almatica Pharma LLC | $143.66 | 2024-2025 | Loreev Xr |
| Bausch Health US, LLC | $85.38 | 2022-2024 | Aplenzin |
| Indivior INC. | $71.15 | 2023-2024 | Perseris |
| Livanova USA, INC. | $67.08 | 2021 | |
| Supernus Pharmaceuticals, INC. | $53.07 | 2023-2025 | Qelbree, Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $44.31 | 2023 | Azstarys, Azstarys |
| Neuronetics, INC. | $41.00 | 2020 | |
| Vanda Pharmaceuticals INC. | $37.36 | 2024 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $34.65 | 2021-2024 | Trintellix |
| Braeburn INC. | $18.68 | 2025 | Brixadi |
| Sunovion Pharmaceuticals INC. | $14.95 | 2022 | |
| Luye Pharma (USA) LTD. | $14.59 | 2025 | Erzofri Extended-Release |
| Janssen Biotech, INC. | $9.40 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shlomo Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.